Bosch to unveil new laboratory device for continuous manufacturing
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.
Bosch Packaging Technology will showcase its laboratory expertise for oral solid dosage (OSD) forms at CPHI Worldwide in Madrid.
The new laboratory device Xelum R&D for continuous manufacturing is on open display for the first time. Moreover, visitors can see how the Bosch Pharma Service and Industry 4.0 solutions support pharmaceutical manufacturers in increasing transparency and efficiency of their laboratory processes. “With our wide range of laboratory solutions, we offer our customers an ideal starting position for a fast time-to-market of their pharmaceuticals,“ says Fritz-Martin Scholz, product manager at the Bosch subsidiary Hüttlin.
Reduced development time thanks to continuous production
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production. “The Xelum R&D is the first R&D machine to combine charging, dosing of several ingredients and blending with granulation, drying and discharging in one unit,” Fritz-Martin Scholz explains. In contrast to continual mass flow, the Xelum R&D doses excipients and active ingredients as a discrete mass. This way, customers can dose even smallest amounts of APIs of less than 1%. Individual packages, so-called X-keys, continuously run through the process chain and are removed successively from the machine as packages into bins.
Moreover, the X-key approach makes the product traceable at all times. It reduces the system’s failure susceptibility and process complexity, while increasing the product’s accuracy and quality. Time-consuming scale-up is not needed, since the laboratory device uses the same components as the Xelum production platform. The identical process parameters can be directly transferred 1:1, which leads to a reduced development time. In addition, the customer has the opportunity to move his product to continuous production or to a conventional batch process.
Customer support starts with the formulation
Bosch’s laboratory portfolio supports customers in all development and production phases of OSD forms. Every year, roughly 1,000 experiments with substances for various indications are conducted at the company’s competence center in Schopfheim, Germany. “The key to achieving a fast time-to-market while meeting the highest quality standards is extensive experience and knowhow,” says Dr Marcus Knoell, Head of Pharma Service Solid at Hüttlin. “We offer customers everything from a single source: from formulation and analytical development, to stability tests and bioequivalence studies and dossier preparation.” A specific focus is on scale-up and technology transfer: every product that is developed at the Bosch laboratory is tailored to the customer’s machines, so that they can later manufacture the product in-house.
Seizing the data treasure
At CPHI Worldwide, Bosch also showcases its new data mining service which evaluates existing machine data more effectively to identify and eliminate root causes. “Machine deviations are often classified as ‘human error’ due to misinterpretations or missing information,” Dr Marc Michaelis, expert for continuous production and process verification at Hüttlin, explains. “Yet we
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance